This HTML5 document contains 189 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
wdthttp://www.wikidata.org/prop/direct/
wdtnhttp://www.wikidata.org/prop/direct-normalized/
schemahttp://schema.org/
rdfshttp://www.w3.org/2000/01/rdf-schema#
skoshttp://www.w3.org/2004/02/skos/core#
wikibasehttp://wikiba.se/ontology#
phttp://www.wikidata.org/prop/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n8http://rdf.ncbi.nlm.nih.gov/pubchem/reference/
xsdhhttp://www.w3.org/2001/XMLSchema#
wdshttp://www.wikidata.org/entity/statement/
wdhttp://www.wikidata.org/entity/
n12http://dx.doi.org/10.2147/

Statements

Subject Item
wd:Q34627724
rdf:type
wikibase:Item
schema:description
articolo scientifico bilimsel makale 2011年論文 мақолаи илмӣ مقالهٔ علمی 2011年论文 mokslinis straipsnis מאמר מדעי επιστημονικό άρθρο 2011年论文 наукова стаття, опублікована в лютому 2011 article científic 2011年の論文 научная статья scientific article 2011年论文 мақолаи илмӣ 2011 թուականի Փետրուարին հրատարակուած գիտական յօդուած 2011 nî lūn-bûn vedecký článok vetenskaplig artikel مقالة علمية teaduslik artikkel 2011年论文 artikull shkencor 2011年論文 научни чланак 2011年論文 naučni članak ২০১১-এ প্রকাশিত বৈজ্ঞানিক নিবন্ধ 2011年論文 scienca artikolo article scientifique (publié 2011) 2011年论文 سائنسی مضمون wissenschaftlicher Artikel научни чланак artigo científico wetenschappelijk artikel vitskapeleg artikkel article scientific tudományos cikk artigo científico (publicado na 2011) научна статия videnskabelig artikel (udgivet 2011) 2011年论文 artículo científico publicado en 2011 artigo científico (publicado na 2011) სამეცნიერო სტატია artykuł naukowy 2011 թվականի փետրվարին հրատարակված գիտական հոդված 2011년 논문 artículu científicu espublizáu en 2011 vitenskapelig artikkel บทความทางวิทยาศาสตร์ tieteellinen artikkeli articol științific vědecký článek artikulong pang-agham 2011年論文 bài báo khoa học
p:P577
wds:Q34627724-3E2D0995-E437-40F1-8DB6-FA3A2B4D5A6C
wdt:P577
2011-02-17T00:00:00Z
p:P407
wds:Q34627724-92695E33-53E1-4880-9307-5EB3EFDB897F
wdt:P407
wd:Q1860
p:P2860
wds:Q34627724-9C36720A-ADA9-428E-BD20-5A9CF10206C9 wds:Q34627724-9EC1BD3C-18A6-4D13-A749-4A46B664A1CD wds:Q34627724-A4EAF0A9-4D48-4CE0-AE69-F7A4A1FF3BF3 wds:Q34627724-A6C8CE96-64BA-4F8F-B3E5-3F613201AFCC wds:Q34627724-ACB0C5ED-69AC-4843-B7B4-2CC67167916B wds:Q34627724-BEEF7161-6C50-4909-B243-9DF284E0A0E6 wds:Q34627724-C397E11F-0771-4D52-AFD6-C61118841A3F wds:Q34627724-C6CD8E23-27A9-4B82-B534-05C494B9C829 wds:Q34627724-C70A551D-FB32-4E89-9AB0-AE06ECBC2616 wds:Q34627724-C87E44C3-5DA7-42D4-A34D-8811FCC5CDE3 wds:Q34627724-D11AA5D4-B76E-4938-93AC-5DA8D26D9F99 wds:Q34627724-D9840A50-4136-47A0-87FB-01E5481A0D47 wds:Q34627724-DB599730-3191-4C06-9539-7A5D86F8EE15 wds:Q34627724-DBF8421D-C928-47CC-9A05-FACA4216CD55 wds:Q34627724-DD26A14D-D70A-4157-A14C-982A36C98A70 wds:Q34627724-E62EBA5E-C8BE-4C50-8C4C-0170824BC4AD wds:Q34627724-EFB7BC26-15D3-4721-BC34-1ADAD2914008 wds:Q34627724-F1A8E69B-BC02-4F50-B405-ECDE8D2F9ACC wds:Q34627724-F25A3FC6-3BF4-486E-A641-F09713033431 wds:Q34627724-F427FF9E-D96A-4C43-900C-0B877BCFB2D6 wds:Q34627724-F84882D2-5E14-48F6-8628-11C8070D1AED wds:Q34627724-FA06F0DD-3A96-466D-8992-44D302543E11 wds:Q34627724-08E1EDC4-1EBF-47B3-92EB-78985AB67207 wds:Q34627724-0E6C2BFC-046C-43D3-8C22-7F84D124F908 wds:Q34627724-15EF2A55-0892-4DCB-BED8-282CA3CA1256 wds:Q34627724-18108D6B-5209-41F7-9E08-C3E1508C26A5 wds:Q34627724-1A0243CD-87C2-49B1-9A7F-71B2A2C7B6B1 wds:Q34627724-22D4F6AF-6669-40E1-8AF6-C84B706C9D84 wds:Q34627724-371D2E7C-765C-46AA-9D26-7225959092A5 wds:Q34627724-3B55D4B5-4086-4139-9678-14C4A9B731E4 wds:Q34627724-40E0761D-F0D1-4D77-8BCC-1A0E7E828F30 wds:Q34627724-4B364EF8-9D10-4612-9EF3-58479E7DFD57 wds:Q34627724-4D6F1E60-6EAE-46BF-B75D-811CCC47D072 wds:Q34627724-693ED955-F358-4A9C-95FC-AD0BB7DAB5F7 wds:Q34627724-6CAB2B8C-24B9-4CE6-8EF4-AB61C480521C wds:Q34627724-70F5B723-F1E1-49F5-8724-318ADF196CC1 wds:Q34627724-71626273-F8A6-4FEA-8568-F13314852C07 wds:Q34627724-747DD15B-C775-487C-AEE8-F3AFF4AFA66A wds:Q34627724-818BBDFB-D6C1-4A31-B883-BCF4F2E7FF05 wds:Q34627724-8717A1A4-DA76-4DD5-8153-0B3F2747599D wds:Q34627724-882F071D-55A2-4324-BF4B-C426965B203C wds:Q34627724-8DF95B9C-349A-4AA2-A78B-D07A845CCBA1 wds:Q34627724-0671C768-30C2-4DD1-BE54-D54019A0FFF4
wdt:P2860
wd:Q34246891 wd:Q34246898 wd:Q73789537 wd:Q40509707 wd:Q33383626 wd:Q31920939 wd:Q56970780 wd:Q35107962 wd:Q73133179 wd:Q45012594 wd:Q46652866 wd:Q56970710 wd:Q46000981 wd:Q44526964 wd:Q44417511 wd:Q29615215 wd:Q79548317 wd:Q57704023 wd:Q24649685 wd:Q36801397 wd:Q44588075 wd:Q34673532 wd:Q24670544 wd:Q34246882 wd:Q44484610 wd:Q73320841 wd:Q22306384 wd:Q46227448 wd:Q80519503 wd:Q73789551 wd:Q46051449 wd:Q35696476 wd:Q73789544 wd:Q36799139 wd:Q46006727 wd:Q44894009 wd:Q35203451 wd:Q44262753 wd:Q43637402 wd:Q46128519 wd:Q43594877 wd:Q56970676 wd:Q37368689
p:P2093
wds:Q34627724-559482B3-701F-4069-B3A8-2D0FDFF1365F wds:Q34627724-06A7F6CC-6B9C-4211-92F0-CEA7C45CA012
wdt:P2093
Bernhard Landers Gerd Bönner
rdfs:label
Candesartan cilexetil/hydrochlorothiazide combination treatment versus high-dose candesartan cilexetil monotherapy in patients with mild to moderate cardiovascular risk (CHILI Triple T). Candesartan cilexetil/hydrochlorothiazide combination treatment versus high-dose candesartan cilexetil monotherapy in patients with mild to moderate cardiovascular risk (CHILI Triple T). Candesartan cilexetil/hydrochlorothiazide combination treatment versus high-dose candesartan cilexetil monotherapy in patients with mild to moderate cardiovascular risk
skos:prefLabel
Candesartan cilexetil/hydrochlorothiazide combination treatment versus high-dose candesartan cilexetil monotherapy in patients with mild to moderate cardiovascular risk (CHILI Triple T). Candesartan cilexetil/hydrochlorothiazide combination treatment versus high-dose candesartan cilexetil monotherapy in patients with mild to moderate cardiovascular risk Candesartan cilexetil/hydrochlorothiazide combination treatment versus high-dose candesartan cilexetil monotherapy in patients with mild to moderate cardiovascular risk (CHILI Triple T).
schema:name
Candesartan cilexetil/hydrochlorothiazide combination treatment versus high-dose candesartan cilexetil monotherapy in patients with mild to moderate cardiovascular risk (CHILI Triple T). Candesartan cilexetil/hydrochlorothiazide combination treatment versus high-dose candesartan cilexetil monotherapy in patients with mild to moderate cardiovascular risk Candesartan cilexetil/hydrochlorothiazide combination treatment versus high-dose candesartan cilexetil monotherapy in patients with mild to moderate cardiovascular risk (CHILI Triple T).
p:P50
wds:Q34627724-9430C3D8-1CD2-40A5-BCEB-BC9536BD8556
wdt:P50
wd:Q38544128
p:P1476
wds:Q34627724-5176B4FD-5BA4-423F-9A1E-9586DFAA6633
wdt:P1476
Candesartan cilexetil/hydrochlorothiazide combination treatment versus high-dose candesartan cilexetil monotherapy in patients with mild to moderate cardiovascular risk (CHILI Triple T)
p:P304
wds:Q34627724-BF78BFC5-29D3-4D0A-8640-85CAD6356BBE
wdt:P304
85-95
p:P31
wds:Q34627724-637FAD71-3355-49B9-A4B5-4F65FAC2EF8C
wdt:P31
wd:Q13442814
p:P698
wds:Q34627724-424BDA2E-C17B-4AC2-8F0C-94D38D26FF5A
wdtn:P698
n8:21415922
wdt:P698
21415922
p:P1433
wds:Q34627724-5B459144-F6FD-4106-9297-06C062515FB0
wdt:P1433
wd:Q7916443
p:P478
wds:Q34627724-DEDAE427-48A4-4C99-B682-4FA1D6CB8800
wdt:P478
7
p:P356
wds:Q34627724-201A6F07-8DDF-4331-938C-B6DD43F48AB2
wdtn:P356
n12:VHRM.S17004
wdt:P356
10.2147/VHRM.S17004
p:P275
wds:Q34627724-341481cc-47a2-41b3-91db-a9be59f83649
p:P6216
wds:Q34627724-e14ab2c1-0b99-4f91-8f32-fda01c035ab8
wdt:P275
wd:Q18810331
wdt:P6216
wd:Q50423863
p:P932
wds:Q34627724-953AD76F-9DDF-4960-9151-C0D248E31F7B
wdt:P932
3049544